Titan Pharmaceuticals, Inc., together with its subsidiaries, operates as a biopharmaceutical company that develops proprietary therapeutics for the treatment of central nervous system disorders, cardiovascular disease, bone disease, and other disorders. Its products include Probuphine, a Phase III clinical trial product for the treatment of opioid dependence; Iloperidone, a Phase III clinical trial product for the treatment of schizophrenia and related psychotic disorders; and Spheramine, a Phase IIb clinical trial product for advanced Parkinson’s disease. The company’s products also include DITPA, a Phase II clinical trial product for the treatment of cardiovascular disease and hyperlipidemia; and Gallium maltolate, a Phase I clinical trial product for chronic bacterial infections, bone disease, and cancer. It has collaborations with Bayer Schering Pharma AG for the development of Spheramine and Vanda Pharmaceuticals, Inc. for the development of Iloperidone. Titan Pharmaceuticals was founded in 1992 and is based in South San Francisco, California.